Saturday 17 October 2026
Export KNSA’s income statement to Excel — free account
Kiniksa Pharmaceuticals International, plc
KNSA Healthcare Drug Manufacturers Specialty & Generic
Kiniksa Pharmaceuticals International, plc’s revenue for fiscal 2025 (year ended December 2025) was $677.6 million, up 60.1% from fiscal 2024. In the quarter to June 2026, revenue grew 55.4%, EPS grew 37.5% and free cash flow grew 66.6%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for five.
78.59
1.35
−1.69%
Follow KNSA
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | — | — | — | — | 3 | 4 | 8 |
P/E ratio |
— | — | — | — | — | 0.00 | 5.47 | 97.53 | 0.00 | 51.56 |
P/S ratio |
— | — | — | — | — | 0.00 | 4.55 | 4.80 | 3.34 | 4.52 |
Altman Z-Score |
— | — | — | — | — | 4.80 | 9.38 | 8.00 | 5.66 | 10.35 |
Altman Z″-Score (non-manufacturers) |
— | — | — | — | — | (5.64) | 6.00 | 4.64 | 2.40 | 5.08 |
P/FCF ratio |
— | — | — | — | — | 0.00 | 177.86 | 97.89 | 55.34 | 22.42 |
Beneish M-Score |
— | — | — | — | — | — | 4.22 | (2.01) | (2.43) | (3.16) |
P/Operating CF |
— | — | — | — | — | (42.74) | (86.55) | 300.16 | 75.27 | 56.79 |
P/B ratio |
— | — | — | — | — | 4.36 | 2.53 | 2.96 | 3.22 | 5.39 |
Price to Tangible BV |
— | — | — | — | — | 4.87 | 2.65 | 3.08 | 3.35 | 5.54 |
EV/Sales |
— | — | — | — | — | 0.00 | 3.68 | 4.04 | 2.76 | 3.91 |
EV/EBITDA |
— | — | — | — | — | 0.00 | 66.63 | 0.00 | 0.00 | 33.60 |
EV/Operating CF |
— | — | — | — | — | (4.95) | 139.71 | 82.09 | 45.51 | 19.18 |
EV/FCF |
— | — | — | — | — | (4.26) | 144.02 | 82.33 | 45.80 | 19.39 |
Quick Ratio |
24.36 | 2.62 | 7.22 | 8.39 | 10.16 | 4.15 | 4.32 | 3.58 | 2.84 | 3.09 |
Current Ratio |
24.47 | 2.70 | 7.37 | 8.68 | 10.46 | 4.38 | 5.16 | 4.34 | 3.30 | 3.79 |
Net Debt/EBITDA |
2.34 | 0.70 | 2.85 | 1.39 | 2.09 | 1.18 | (15.66) | 9.03 | 5.55 | (5.26) |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.13 | 0.64 | 0.55 | 0.76 | 1.01 |
Operating CF/Net income |
0.91 | 0.77 | 0.78 | 0.98 | 0.85 | 0.80 | 0.03 | 0.94 | (0.59) | 2.34 |
Capex/Depreciation |
(0.14) | (2.46) | (18.50) | (1.55) | (0.12) | (8.67) | (0.01) | (0.06) | (0.15) | (1.01) |
| 41.53% | 112.39% | (108.91%) | (64.15%) | (60.06%) | (63.55%) | 63.10% | 3.37% | (9.85%) | 11.73% | |
| (46.12%) | (124.80%) | (55.88%) | (56.16%) | (53.44%) | (54.24%) | 52.96% | 2.86% | (7.80%) | 8.78% | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (3,451.96%) | 2.97% | (6.77%) | (14.63%) | 31.44% |
Return on Tangible Assets |
(44.30%) | (217.70%) | (37.19%) | (73.51%) | (52.83%) | (102.25%) | 92.77% | 6.60% | (18.63%) | 15.13% |
Average Days of Receivables |
— | — | — | — | — | 37.74 | 20.99 | 28.72 | 35.98 | 8.40 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 257.62% | 29.74% | 28.16% | 26.37% | 14.29% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 222.99% | 44.49% | 47.89% | 39.70% | 28.97% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.08 | 0.04 | 0.03 | 0.03 | 0.02 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 65.31% | 11.41% | 10.05% | 7.25% | 5.46% |
Graham Net Nets |
— | — | — | — | — | 0.18 | 0.18 | 0.15 | 0.13 | 0.11 |
Graham Number |
— | — | — | — | — | 0.00 | 18.42 | 5.17 | 0.00 | 11.73 |
Earnings Yield |
— | — | — | — | — | (19.54%) | 18.28% | 1.03% | (3.08%) | 1.94% |
Free Cash Flow Yield |
— | — | — | — | — | (18.18%) | 0.56% | 1.02% | 1.81% | 4.46% |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.56 | 3.17 | 3.86 | 5.93 | 9.13 |
Operating CF per Share |
(83.56) | (27.75) | (2.74) | (2.93) | (2.21) | (1.84) | 0.08 | 0.19 | 0.36 | 1.86 |
Capex per Share |
(0.01) | (0.04) | (0.18) | (0.06) | 0.00 | (0.30) | 0.00 | 0.00 | 0.00 | (0.02) |
Free Cash Flow per Share |
(83.57) | (27.78) | (2.92) | (2.99) | (2.21) | (2.14) | 0.08 | 0.19 | 0.36 | 1.84 |
Cash per Share |
214.27 | 25.23 | 10.40 | 4.32 | 5.23 | 2.66 | 2.75 | 2.95 | 3.41 | 5.58 |
Shareholders Equity per Share |
206.97 | 16.61 | 9.45 | 4.17 | 5.04 | 2.70 | 5.71 | 6.26 | 6.14 | 7.65 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
206.97 | 16.61 | 9.45 | 4.17 | 5.04 | 2.70 | 5.71 | 6.26 | 6.14 | 7.65 |
Free Cash Flow |
(21.87) | (50.29) | (86.30) | (161.57) | (136.81) | (146.71) | 5.79 | 13.17 | 25.44 | 136.42 |
Working Capital |
54.03 | 29.67 | 271.20 | 213.80 | 301.40 | 151.62 | 195.99 | 212.63 | 231.18 | 387.99 |
Capital Expenditures |
0.00 | (0.07) | (5.29) | (3.20) | (0.28) | (20.41) | (0.01) | (0.13) | (0.25) | (1.57) |
Net Current Asset Value |
54.03 | 29.67 | 271.05 | 212.52 | 295.72 | 148.68 | 179.54 | 188.81 | 189.68 | 331.15 |
EV/EBIT |
— | — | — | — | — | 0.00 | 83.01 | 0.00 | 0.00 | 34.27 |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.53 | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Operating Income |
— | — | — | — | — | 0.00 | 102.51 | 0.00 | 0.00 | 39.64 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.26 | 0.22 | 0.05 | 0.32 | 0.59 | 0.83 | 1.45 | 3.19 | 2.56 | 0.80 |
Cash ROIC |
(19.84%) | (66.41%) | (14.71%) | (35.22%) | (21.52%) | (39.95%) | 0.99% | 2.04% | 3.73% | 13.90% |
Accounts Receivable Turnover |
— | — | — | — | — | 0.00 | 26.46 | 15.93 | 13.44 | 23.64 |
Accounts Payable Turnover |
0.03 | 0.04 | 0.05 | 0.39 | 1.23 | 7.68 | 4.69 | 4.14 | 11.84 | 38.20 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.81 | 1.27 | 2.12 | 1.91 |
Average Days of Payables |
3,517.27 | 15,877.50 | 13,933.81 | 633.71 | 48.25 | 74.93 | 125.93 | 90.09 | 12.22 | 9.53 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 147.40 | 344.34 | 340.03 | 157.98 | 257.96 |
Average Receivables |
— | — | — | — | — | — | 8.32 | 16.96 | 31.50 | 28.66 |
Average Payables |
0.72 | 0.72 | 6.07 | 8.31 | 3.10 | 1.19 | 4.88 | 8.07 | 5.14 | 2.03 |
Average Inventory |
— | — | — | — | — | — | 12.64 | 26.36 | 28.74 | 40.63 |
Average Assets |
51.98 | 51.98 | 184.73 | 288.25 | 302.00 | 291.13 | 346.24 | 493.00 | 553.44 | 672.09 |
Average Common Equity |
(57.72) | (57.72) | 94.78 | 252.35 | 268.68 | 248.49 | 290.59 | 417.49 | 438.64 | 503.02 |
Columns are period end dates